ArticleCancer communications (London, England)2024

Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity.

Sung Hee Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.